1 / 27

Pheochromocytoma

Pheochromocytoma. Leah Olsson SRNA Rush University. ~Discuss physiology of pheochromocytomas and treatment ~Review: preoperative intraoperative postoperative treatment. Objectives. Pheochromocytomas. Catecholamine secreting tumor of chromaffin tissues

zinnia
Télécharger la présentation

Pheochromocytoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pheochromocytoma Leah Olsson SRNA Rush University

  2. ~Discuss physiology of pheochromocytomas and treatment ~Review: preoperative intraoperative postoperative treatment Objectives

  3. Pheochromocytomas • Catecholamine secreting tumor of chromaffin tissues • Pheochromocytomas can be found anywhere chromaffin tissues exist

  4. Dusky (pheo) Color (chromo) Pheochromocytomas produce store and secrete catecholamines epinephrine norepinephrine

  5. Signs and Symptoms • HTN • Tachycardia • Diaphoresis • Headaches • Tremulousness • Weight loss • Palpitations • Orthostatic hypotension • (Stoelting & Dierdorf 2002)

  6. Pheochromocytoma Triad • Diaphoresis • Tachycardia • Headaches

  7. <0.5% of hypertensive patients are diagnosed with pheochromocytoma • Usually in patients 30-50 yrs. But can occur at any age. • Male=Female • (Nagelhout & Zaglaniczy, 2005)

  8. Typically benign and unilateral. 10-15% are malignant 10-15% are bilateral (Morgan, Mikhail, & Murray, 2006)

  9. Diagnosis • Blood catecholamine levels • Pheochromocytomas are found on CT and MRI.

  10. Diagnosis • 24hr urine collection • free norepinephrine • tumor secretes catecholamines intermittently • catecholamines have a short half life. • (Stoelting & Dierdorf 2002)

  11. Diagnosis • Vanillymandelic acid (VMA). • Final common product of both catecholamine metabolic pathways • Often used as an initial test r/t specificity and sensitivity. ↓ cost

  12. Diagnosis • Clonidine suppression test: PO clonidine 0.3mg will suppress catecholamine secretion in hypertensive pts not in pt with pheochromocytomas • (Yao, Fontes, & Malhotra 2008 )

  13. Treatment Surgical removal of the tumor Optimizing pt prior to surgery is most important for desirable surgical outcomes

  14. Preoperative considerations • α-Adrenergic blockade should be started 10-14 days prior to surgery. • Phenoxybenzamine 10-20 mg qd. With increasing dose PRN • Decreases or prevents catecholamine-induced vasoconstriction. • Normalize BP and intravascular volume prior to surgery will assist in keeping the pt stable during resection of the catecholamine secreting tumor

  15. Selective α1-blockers Prazosin and doxazosin Shorter DOA Easier dose adjustment ↓ postop hypotension ↓reflex tachycardia presynaptic α-receptors are not blocked α-blockade

  16. If tachycardia persists then a beta blocker should be used. β blockade should only be administered if the pt is concurrently taking an αblocker. Unopposed α-mediated vasoconstriction has the potential to place the patient in CHF or can result cardiac arrest. Labetalol and atenolol Preoperative considerationsβ-blockers

  17. Suggested drugs to avoid • Droperidol • Morphine • Atracurium • Pancuroium • Ketamine • Ephedrine • Halothane • Cocaine • Metoclopramide • Curare • (Yao, Fontes, & Malhotra 2008 )

  18. Intraoperative management • Careful consideration should be taken when choosing drugs. • Stimulation of the SNS should be avoided • Premedicate pt to decrease anxiety! • A-line placed prior to induction. • PA cath +/- pt specific consider in pt with ↓ cardiac reserve, CHF • 2 Large bore IVs

  19. Intraoperative considerations • Three critical phases of tumor resection are • 1) Induction and intubation • 2) Surgical manipulation • 3) After ligation of the tumors venous drainage • (Nagelhout & Zaglaniczy 2005)

  20. Induction & Intubation • Etomidate, thiopental, and propofol can all be used to initiate anesthesia. • Increase anesthetic depth by bag mask ventilation with volatile anesthetic • Lidocaine 1-2mg/kg 1 min prior to induction • Narcotics • Fast acting antihypertensive readily available • (Nagelhout & Zaglaniczy 2005)

  21. Maintenance • Anesthesia is maintained with gases and narcotics. VA are easy to titrate, can help with HTN (1.5-2 MAC) • Pt should be kept normovolemic. • Blood glucose monitoring

  22. HTN Nipride gtt . Side effect: reflex tachycardia cyanide poisoning r/t ↑ infusion time Nicardipine gtt Hypotension volume expansion and decreased anesthetic gases (Stoelting & Dierdorf 2002) Indirect acting sympathomimetics should be avoided r/t unpredictable effects (Nagelhout & Zaglaniczy 2005) BP treatment

  23. Ligation of the tumors venous drainage • ↓ circulating catecholamine causing hypotension • After ligation of all venous drainage arterial pressure commonly declines r/t ↑CO, ↓ SVR Treatment • ↓ VA • ↑ IVF • Phenylephrine or norepinephrine

  24. Postop • Invasive lines should stay intact. Pt still at risk for liable BP. • Pt susceptible to hypotension that is refractory to fluid volume expansion.

  25. Still have high volumes of circulating catecholamine despite tumor resection Catecholamine levels normalize after several days. 75% of pts BP returns to normal after 10 days (Nagelhout & Zaglaniczy 2005) Prone to Hypoglycemia. Secondary to suppression of β-cell function disappears after the tumor is removed (Yao, Fontes, & Malhotra 2008 ) Postop

  26. Conclusion • Pheochromocytoma-physiology • Preoperative-pt optimization- proper pharmacologic tx • Intraoperative-induction-maintenance. Tx for liable BP

  27. References • Morgan, G. E., Mikhail, M. S, Murray, M. J. (2006). Clinical Anesthesiology (4th ed.). New York: McGraw Hill. • Nagelhout, J. J., Zaglaniczny, K. L. (2005). Nurse Anesthesia (3rd ed.). St. Louis: Elsevier Sanders. • Yao, F. F., Fontes, M. L., Malhotra, V. (2008). Anesthesiology: problem oriented patient management (6th ed.). Philadelphia: Lippincott Williams & Wilkins. • Stoetling, R. K., Dierdorf, S. F., (2002). Anesthesia and Co-existing Disease (4th ed.). Philadelphia: Churchill Livingstone.

More Related